Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $275.00 at Bank of America

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective boosted by stock analysts at Bank of America from $263.00 to $275.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Bank of America‘s price objective points to a potential upside of 58.20% from the company’s current price.

A number of other equities research analysts have also weighed in on the company. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Wells Fargo & Company raised their price target on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. UBS Group reissued a “neutral” rating and set a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $207.53.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $173.83 on Wednesday. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. The firm has a market cap of $10.56 billion, a PE ratio of -28.64, a P/E/G ratio of 0.93 and a beta of 0.26. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $182.99. The stock has a fifty day moving average price of $168.08 and a 200-day moving average price of $150.27.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the completion of the transaction, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,200,454.40. This represents a 39.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president directly owned 19,508 shares in the company, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of JAZZ. Hilltop National Bank purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $36,000. LRI Investments LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Farther Finance Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares during the period. Leonteq Securities AG purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $50,000. Finally, GoalVest Advisory LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 and FY2025 results topped Street estimates: Jazz reported Q4 revenue of ~$1.2B and EPS above consensus; full‑year 2025 revenue hit a record ~$4.3B. Investors are reacting to the beat and continued top‑line growth. Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
• Positive Sentiment: Key growth drivers: Xywav grew to ~$1.7B (12% YoY) and Epidiolex ~$1.1B (9% YoY), showing durable demand across core franchises — a major support for revenue momentum. Jazz Pharmaceuticals beats estimates on strong Xywav growth
• Positive Sentiment: Early‑stage commercial upside: Modeyso posted $37M in its first full quarter, indicating a solid early launch contribution that investors will watch to see scale. Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
• Positive Sentiment: Near‑term regulatory catalyst: Jazz expects to complete an sBLA for zanidatamab (HER2+ 1L GEA) in 1Q26 under the FDA’s RTOR program — a potential oncology approval/launch driver. Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches
• Neutral Sentiment: 2026 revenue guidance set to $4.25B–$4.50B — roughly in line with Street expectations but with a midpoint that’s marginally below some consensus forecasts; this frames 2026 as a growth continuation but not an accelerating beat. Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches
• Neutral Sentiment: Analyst/estimate context: Coverage notes show Jazz beat quarterly revenue and EPS estimates but key metrics (margins, guidance details) will determine whether analysts raise targets; watch commentary from the earnings call and slide deck for conviction. Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance/detail risks: EPS guidance detail was limited/unclear in initial commentary and the revenue range leaves room for downside vs. upside surprises; absence of a clear beat‑and‑raise on guidance could cap upside near term. Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.